Dec 04, 2020 08:26 PM (GMT+8) · EqualOcean
Kanghong pharmaceutical announced that the company plans to issue A-share shares in a non-public way. The total amount of capital to be raised in this non-public offering is not more than 3.472 billion yuan (including 3.472 billion yuan). After deducting the issuing expenses, the company will invest in the international phase III clinical trial and registered listing project of conbercept ophthalmic injection, and the international phase III clinical trial for RVO / DME indications of conbercept eye injection The project includes inspection and registration projects, construction projects of chemical raw material drug bases, and projects of genuine medicinal materials planting bases and seedling centers.

This text is a result of machine translation.